Fujimoto, Yumi
Morita, Tomoko Yamamori
Ohashi, Akihiro
Haeno, Hiroshi
Hakozaki, Yumi
Fujii, Masanori
Kashima, Yukie
Kobayashi, Susumu S.
Mukohara, Toru
Funding for this research was provided by:
National Cancer Center Research and Development Fund (31-A-6)
Japan Society for the Promotion of Science (16K21746)
Grant-in-Aid for Scientific Research (15K08588)
Article History
Received: 29 May 2020
Accepted: 23 November 2020
First Online: 10 December 2020
Competing interests
: A.O. was an employee of Takeda Pharmaceutical Company, Ltd from 2006 to 2018, and reported paid consulting or advisory roles for Ono Pharmaceutical Company Ltd. out of this study. H.H. has research grant from SRL, Miraka Research Institute, and Boehringer Ingelheim Japan. S.S.K. has research grant from Taiho Pharmaceutical, Boehringer Ingelheim, and MiNA therapeutics, consulting fees from Pfizer and Ono Pharmaceutical, and honoraria from Chugai Pharmaceutical, Boehringer Ingelheim, and Roche Diagnostic. T.M. has research grant from Pfizer, Daiichi Sankyo, MSD, Sysmex, Eisai, Sanofi, and Bristol-Myers Squibb. Y.F., A.O., T.Y.M., Y.H., M.F., and Y.K. declare no competing interests.